Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.
The company's management has also recommended its shareholders vote against resolutions to remove members of its board at an upcoming shareholder meeting.
The company's stock faced delisting for trading below $1 for 30 consecutive business days in violation of the Nasdaq's requirements.
The company said that an effort by a group of shareholders to oust the company's management may impact the strategic review process.
The company said it is considering all transactions that would boost shareholder value including a merger or sale of its assets.
The Australian molecular diagnostics firm received 265 test samples during the quarter, including 140 tests issued to Ohio State University as part of an agreement.
The company said it has been notified that its shares fail to meet the Nasdaq's $1 minimum bid price requirement.
The company is switching from an insurance-based model to a direct patient self-pay system for its BrevaGenplus breask cancer risk assessment assay.
The company plans to use the proceeds to expand its breast cancer risk test and to develop and commercialize a risk assessment test for colorectal cancer.
The technology involves analyzing susceptibility SNPs in order to predict a patient's likelihood of developing colorectal cancer.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.